Overview

Dymista Allergen Chamber - Onset of Action Study

Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
This study is to assess the onset of action of fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray (Dymista) in treating the nasal symptoms of seasonal allergic rhinitis (SAR) induced by an allergen challenge in an Environmental Exposure Unit (EEU).
Phase:
Phase 4
Details
Lead Sponsor:
MEDA Pharma GmbH & Co. KG
Treatments:
Azelastine
Fluticasone
Xhance